Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?

Nature Clinical Practice Urology volume 3, pages 310–311 (2006)Cite this article

boxed-textRozhansky F et al. (2006) Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106: 63–67

PSA kinetics might reflect biologic activity in a clinically useful manner; however, careful consideration of many confounders is required before PSA kinetics should be allowed to influence clinical care

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Svatek RS et al. (2006) Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 106: 1047–1053

    Article  Google Scholar 

  2. Nelson JB et al. (2006) Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naïve prostate cancer [abstract #137]. ASCO 2006 Prostate Cancer Symposium

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Chief of Urologic Oncology at the Nevada Cancer Institute, Las Vegas, NV, USA

    John F Ward

Authors
  1. John F Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John F Ward.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ward, J. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?. Nat Rev Urol 3, 310–311 (2006). https://doi.org/10.1038/ncpuro0504

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0504

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing